Sort
40,608 grants matching “prostate cancer”
NEW AWARD - IDENTIFICATION OF THERAPEUTIC VULNERABILITY IN PROSTATE CANCER HARBORING CHROMOSOME 17P LOSS...SIGNED 4/7/2020, EFFECTIVE 9/1/2020, DISTRIBUTED 4/8/2020, FAADC 4/13/2020
$1,151,119Trustees Of Indiana University · · FY2020 · Defense Health Agency
TARGETING BASAL-LIKE PROSTATE CANCER WITH CADHERIN 3 ANTIBODY-DRUG CONJUGATE AS SINGLE AGENT AND IN COMBINATION WITH IMMUNOTHERAPY
$1,150,994University Of Notre Dame Du Lac · · FY2020 · Defense Health Agency
REDUCING TOXICITY OF RADIATION TREATMENT OF ADVANCED PROSTATE CANCER
$1,150,956Thomas Jefferson University · · FY2012 · Department of the Army
Pharmacogenetic Studies
$1,150,824Neil E. Caporaso · Division Of Cancer Epidemiology And Genetics · ZIA · FY2011 · CA
Pharmacogenetic Studies
$1,150,747Neil E. Caporaso · Division Of Cancer Epidemiology And Genetics · ZIA · FY2013 · CA
Role of Neurotrophins in the Development of the Mammalian Nervous System
$1,150,610Lino Tessarollo · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Development of small molecule therapeutics targeting AR-V7 for prostate cancer
$1,150,471Cheuk Man Cherie Au · Arma Bio, Inc. · R44 · FY2025 · CA
Finding Genes for Human Prostate Cancer
$1,150,252Elaine Ostrander · National Human Genome Research Institute · ZIA · FY2017 · HG
Center for Advanced Imaging Innovation and Research (CAI2R)
$1,150,209Daniel K Sodickson · New York University School Of Medicine · P41 · FY2015 · EB
Biomarkers in Cancer Diagnosis, Prognosis and Therapeutic Outcome
$1,150,123Curtis Harris · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Integrative Molecular Epidemiology of Human Cancer
$1,150,123Curtis Harris · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors
$1,150,000Kenneth Schultz · Trethera Corporation · R44 · FY2025 · CA
Commercialization of Algorithmic Non-thermal Ablation Technology for the Treatment of Inoperable Tumors
$1,150,000Jordan Fong · Gradient Medical, Inc. · R42 · FY2025 · CA
THE ROLE OF MUTATIONS IN BRCA2 AND OTHER KNOWN AND NOVEL CANCER SUSCEPTIBILITY GENES IN INHERITED RISK FOR LETHAL PROSTATE CANCER
$1,149,885The Johns Hopkins University · · FY2016 · Department of the Army
Image Guided Therapy
$1,149,604Ferenc A Jolesz · Brigham And Women'S Hospital · P01 · FY2010 · CA
Genomewide Association Study of Prostate Cancer
$1,148,946John S Witte · University Of California, San Francisco · U01 · FY2009 · CA
FUNCTIONAL VALIDATION OF PROSTATE CANCER DRIVING MUTATIONS
$1,148,298The Johns Hopkins University · · FY2011 · Department of the Army
3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Center
$1,148,169Mariana C Stern · University Of Southern California · U54 · FY2025 · CA
BPTF-MEDIATED GENE REGULATION IN PROSTATE CANCER
$1,147,868University Of Maryland, Baltimore · · FY2022 · Department of the Army
Development and Translation of Hyperpolarized C-13 Prostate Cancer MRI Methods
$1,147,784Daniel B Vigneron · University Of California, San Francisco · R01 · FY2014 · EB
A Genome-wide Association Study of Prostate Cancer in African Americans
$1,147,733Brian E Henderson · University Of Southern California · U01 · FY2011 · CA
Metal Chelate Conjugated Monoclonal Antibodies for Tumor Diagnosis and Therapy
$1,147,554Martin W Brechbiel · Division Of Clinical Sciences - Nci · ZIA · FY2013 · CA
TREATMENT OF PROSTATE CANCER USING TARGETED RADIONUCLIDE THERAPY (TRT) WITH TUMOR-SPECIFIC T-CELL ACTIVATION
$1,147,476University Of Wisconsin System · · FY2019 · Department of the Army
Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
$1,146,945Saundra Buys · University Of Utah · N01 · FY2010 · CA
GENETIC EPIDEMIOLOGY OF LUNG CANCER
$1,146,780University Of Cincinnati · U01 · FY2000 · CA